Summary A Delphi consensus, funded by an immunotherapy manufacturer, was reached on Depot Venom Immunotherapy (dVIT). dVIT safety is similar to aqueous VIT (rush and ultra‐rush protocols), with immunological specific enhancements.
Pravettoni et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: